Core Insights - Predictive Oncology Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000, allowing its shares to continue trading on the Nasdaq Capital Market under the ticker "POAI" [1] - The company is focusing on a digital asset strategy centered around the Aethir network's native utility token, ATH, as part of its transformational treasury strategy [1][3] Company Overview - Predictive Oncology utilizes artificial intelligence and machine learning to enhance early drug discovery, particularly for cancer treatment, with a platform called PEDAL that predicts drug response with 92% accuracy [2] - The company has access to a biobank of over 150,000 human tumor samples, providing a comprehensive AI-based drug discovery solution [2] Digital Asset Strategy - The company operates a digital asset treasury focused on the ATH token, aiming to create a Strategic Compute Reserve and enhance the Aethir ecosystem's infrastructure for AI [3]

Institutional Investment - Institutional flows dominated Q3, driven by spot BTC and ETH ETFs attracting over $18 billion in inflows [1] - Public firms increased their BTC holdings by 190,000, representing 5% of the total supply [1] Altcoin Treasuries - Altcoin treasuries are increasing, with ETH, SOL, TRX, WLD, and ATH leading the way [1]

Core Insights - Predictive Oncology has successfully closed two private investment in public equity transactions (PIPEs) totaling approximately $343.5 million to support its digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem [1][2] Investment Details - The PIPEs consist of two components: - A cash PIPE raising approximately $50.8 million through the sale of about 4.4 million shares of common stock at a price of $11.6265 per share [2] - A crypto PIPE involving pre-funded warrants to purchase up to approximately 14.9 million shares of common stock for a purchase price of $11.6165 per warrant, in exchange for approximately $292.7 million in notional value of ATH contributions [2] - The PIPEs closed on October 7, 2025, and the pre-funded warrants will be exercisable following shareholder approval [2][4] Strategic Intent - The company aims to utilize the in-kind contribution of ATH to fund its digital asset treasury strategy and acquire ATH in the open market, alongside working capital and general corporate purposes [4] - The investment aligns with the company's computational needs and capital requirements as it seeks to lead in AI-driven drug discovery [5] Company Background - Predictive Oncology leverages AI and machine learning for drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [9] - The company has a biobank of over 150,000 tumor samples, enhancing its AI-based drug discovery capabilities [9] Aethir Overview - Aethir is a decentralized physical infrastructure network providing GPU resources for AI computation, gaming, and cloud workloads, aiming to democratize access to AI infrastructure [7][8] - ATH serves as a utility token within the Aethir ecosystem, facilitating GPU rentals, staking, and rewards [8]

Market Performance - Top gainers in the last 7 days include $STBL, $AVNT, $UB, $OVPP, $DORA, $TOSHI, $CCD, $ATH, and $FLZ [1] - $STBL experienced the highest gain at +384% [1] - $AVNT gained +207% [1] - $UB increased by +167% [1] - $OVPP rose by +135% [1] - $DORA increased by +76% [1] - $TOSHI gained +56% [1] - $CCD increased by +50% [1] - $ATH rose by +43% [1] - $FLZ gained +42% [1] Industry Trend - The week was very bullish for low cap altcoins [1]